Inhibikase Therapeutics (IKT) Institutional Ownership $1.80 -0.04 (-2.17%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.80 0.00 (0.00%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)CurrentInstitutional OwnershipPercentage3.81%Number ofInstitutional Buyers(last 12 months)27TotalInstitutional Inflows(last 12 months)$79.87MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$1.84M Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data IKT Institutional Buying and Selling by Quarter Inhibikase Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Perceptive Advisors LLC5,432,293$10.59M0.9%-8.3%7.307% 8/15/2025 Bank of America Corp DE19,216$37K0.0%-57.3%0.026% 8/14/2025 Commodore Capital LP5,397,488$10.53M0.7%+1.0%7.260% 8/14/2025 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.33,023$64K0.0%N/A0.044% 8/13/2025 Stonepine Capital Management LLC733,793$1.43M1.4%-19.8%0.987% 8/13/2025 Invesco Ltd.30,712$60K0.0%N/A0.041% 8/13/2025 New York State Common Retirement Fund60,700$118K0.0%N/A0.082% 8/12/2025 JPMorgan Chase & Co.28,579$56K0.0%N/A0.038% 8/8/2025 Intech Investment Management LLC31,406$61K0.0%N/A0.042% 8/8/2025 Police & Firemen s Retirement System of New Jersey17,638$34K0.0%N/A0.024% Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/8/2025 Geode Capital Management LLC1,066,700$2.08M0.0%+228.5%1.435% 6/27/2025 Goldman Sachs Group Inc.166,025$364K0.0%+277.7%0.223% 5/19/2025 Jane Street Group LLC116,249$255K0.0%N/A0.156% 5/16/2025 Goldman Sachs Group Inc.166,025$364K0.0%+277.7%0.223% 5/16/2025 ADAR1 Capital Management LLC5,122,105$11.22M2.1%+0.4%6.890% 5/14/2025 Stonepine Capital Management LLC914,973$2.00M1.9%-19.2%1.231% 5/9/2025 Blair William & Co. IL155,953$342K0.0%+15.6%0.210% 5/6/2025 Y Intercept Hong Kong Ltd26,775$59K0.0%N/A0.036% 2/27/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/18/2025 Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/17/2025 Soleus Capital Management L.P.6,325,000$20.56M1.3%N/A9.119% 2/17/2025 Squarepoint Ops LLC28,411$92K0.0%N/A0.041% 2/17/2025 Stonepine Capital Management LLC1,132,388$3.68M3.0%N/A1.633% 2/17/2025 OMERS ADMINISTRATION Corp54,600$177K0.0%N/A0.079% 2/17/2025 Millennium Management LLC142,209$462K0.0%N/A0.205% 2/17/2025Jefferies Financial Group Inc.14,800$48K0.0%N/A0.021% 2/17/2025 Fairmount Funds Management LLC6,125,000$19.91M2.0%N/A8.831% 2/17/2025 Blackstone Inc.2,070,684$6.73M0.0%N/A2.985% 2/17/2025 Caxton Corp16,393$53K0.3%N/A0.024% 2/14/2025 Nantahala Capital Management LLC2,190,000$7.12M0.3%N/A3.157% 2/14/2025 Northern Trust Corp64,011$208K0.0%N/A0.092% 2/14/2025 Alpine Global Management LLC14,842$48K0.0%N/A0.021% 2/14/2025 Stifel Financial Corp13,129$43K0.0%N/A0.019% 2/13/2025 Barclays PLC84,000$273K0.0%N/A0.121% 2/13/2025 ADAR1 Capital Management LLC5,103,005$16.59M3.3%N/A7.357% 2/12/2025 Geode Capital Management LLC322,878$1.05M0.0%+544.9%0.466% 2/12/2025 Blair William & Co. IL134,953$439K0.0%+7.0%0.195% 8/15/2024 Armistice Capital LLC589,575$713K0.0%N/A8.170% 11/15/2023 Armistice Capital LLC186,046$259K0.0%-62.5%3.477% 9/21/2023 Barclays PLC11,455$41K0.0%N/A0.214% Washington prepares for war (Ad)While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.Click here now to watch the urgent wartime exposé8/8/2023 Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266% 5/2/2023 Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286% 2/10/2023 Blair William & Co. IL229,000$114K0.0%+27.9%0.817% 7/12/2022 Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259% 5/6/2022 Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461% 5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476% 5/4/2022 Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657% 5/3/2022 Redmond Asset Management LLC122,682$182K0.1%N/A0.486% 2/14/2022 Murchinson Ltd.220,947$327K0.0%-31.2%0.878% 2/8/2022 Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586% 2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279% 11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019% 11/16/2021 Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103% 11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202% 8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926% 8/16/2021 Antara Capital LP250,000$700K0.0%N/A2.467% 8/16/2021 Warberg Asset Management LLC90,000$252K0.0%N/A0.888% 8/16/2021 Sabby Management LLC421,200$1.18M0.2%N/A4.157% 8/13/2021 Altium Capital Management LP109,749$307K0.1%N/A1.083% 8/13/2021 Murchinson Ltd.320,947$899K0.3%N/A3.167% 8/13/2021 Vanguard Group Inc.470,615$1.32M0.0%N/A4.644% 8/13/2021 FMR LLC433,300$1.21M0.0%+333.3%4.276% 8/12/2021 Kepos Capital LP700,000$1.96M0.1%N/A6.908% 5/18/2021 Millennium Management LLC11,224$67K0.0%N/A0.112% (Data available from 1/1/2016 forward) IKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IKT shares? During the previous two years, 30 institutional investors and hedge funds held shares of Inhibikase Therapeutics. The most heavily invested institutionals were Soleus Capital Management L.P. ($20.56M), Fairmount Funds Management LLC ($19.91M), ADAR1 Capital Management LLC ($11.22M), Perceptive Advisors LLC ($10.59M), Commodore Capital LP ($10.53M), Nantahala Capital Management LLC ($7.12M), and Blackstone Inc. ($6.73M).Learn more on Inhibikase Therapeutics' institutional investors. What percentage of Inhibikase Therapeutics' stock is owned by institutional investors? 3.81% of Inhibikase Therapeutics' stock is owned by institutional investors. Learn more on IKT's institutional investor holdings. Which institutional investors have been buying Inhibikase Therapeutics' stock? Of the 28 institutional investors that purchased Inhibikase Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Soleus Capital Management L.P. ($6.33M), Fairmount Funds Management LLC ($6.13M), ADAR1 Capital Management LLC ($5.12M), Nantahala Capital Management LLC ($2.19M), Blackstone Inc. ($2.07M), Stonepine Capital Management LLC ($1.13M), and Geode Capital Management LLC ($1.01M). How much institutional buying is happening at Inhibikase Therapeutics? Institutional investors have bought a total of 25,114,084 shares in the last 24 months. This purchase volume represents approximately $79.87M in transactions. Which of Inhibikase Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Perceptive Advisors LLC ($492.71K), Stonepine Capital Management LLC ($398.60K), and Bank of America Corp DE ($25.81K). How much institutional selling is happening at Inhibikase Therapeutics? Institutional investors have sold a total of 917,112 shares in the last 24 months. This volume of shares sold represents approximately $1.84M in transactions. Related Companies ATYR Major Shareholders ALMS Major Shareholders ARCT Major Shareholders EOLS Major Shareholders BCYC Major Shareholders TECX Major Shareholders NBTX Major Shareholders CGEM Major Shareholders PRME Major Shareholders PRTA Major Shareholders This page (NYSE:IKT) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts